• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172723 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
6 s2 |+ m2 e9 i2 a7 l5 k# a
5 j- y# H* V5 u  u
& B5 Y# a9 Q% x7 h8 l9 p7 BSub-category:
) c0 _3 z& m9 {& W; VMolecular Targets
' z! L$ Q3 |3 i/ |% ]3 p6 u$ I: ]$ z, H6 u

/ ]1 _3 Y3 H. B7 |. \, g6 r$ fCategory:
! j7 G' s1 U( ?Tumor Biology % W5 S  w6 c. @

. X/ u/ S, ]& V# L9 Y  K5 r: m( ]$ p- X$ E+ q8 R6 ^  B6 [
Meeting:9 t3 ~6 \9 k4 ~) A) I/ l/ y
2011 ASCO Annual Meeting
- ~& x. c! B; b/ M" N3 J* f+ c8 H+ u6 ]2 a9 K; `* x6 u9 I$ J
6 Z: t% a$ }* T% G9 u
Session Type and Session Title:
7 b2 l* \7 `' Z: u8 r- hPoster Discussion Session, Tumor Biology ; r5 c+ P( l8 q" K
; S' e* h2 C! I# U7 H6 r* ?" }4 H* ?% j
7 v3 m3 T& j8 y, [, |2 h. y
Abstract No:; z5 `  j( G5 l0 q0 o. ], h6 W
10517
2 W/ g9 c) i+ f0 f, H; R6 s9 V8 s7 `/ `9 m5 g& ?  T
* D, Q" h, c# |) `4 W$ \2 d9 u, e
Citation:
- n5 _- {8 V0 Q$ g' PJ Clin Oncol 29: 2011 (suppl; abstr 10517)
# [: V1 C3 y+ \, H  t( e
* B* l/ p4 p8 ^! ^" Y0 T/ a' r7 Y/ l) i5 P' e0 g
Author(s):, L- E; N4 @6 ^9 h
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 P- a. L7 F+ _6 j( ~* Y& h: P) ~/ X% u
' A- u6 l7 x4 r& P. j- E- \
+ S, x8 ?& t5 K5 m* K/ i
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.* E3 `% w/ t: z9 M) w' V5 F
8 ~+ @" F0 R9 o& c6 @. {
Abstract Disclosures
3 X$ n- U- \4 J& S) y; i: U9 `* _9 N
! f5 I4 S" |% IAbstract:1 I# n6 D" i, h3 P$ Z$ l  a8 f

& y( t* [. _* y1 h$ u  s. I4 E/ R* K  n( }/ s7 j
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
9 n( [3 f) ]2 P  W* {+ L# h4 s
# ^# N" o6 {5 N6 ?; U " |3 p! Y  m7 `, @
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 ( X. u" r7 u8 R* t% u# }
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
% O4 s9 J6 ^5 A5 u2 _3 ?2 v
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 % }! |4 ~; M# |2 ~, }5 ^
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。& G% o: t. f. k) [! y
ALK一个指标医院要900多 ...

/ a! I6 C4 w. _) h2 R平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
6 ^' C/ h$ q2 u* M( N" v, L$ W" D( V* M7 P! `9 D' Y
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表